Fixed combinations of calcium channel blockers and angiotensin converting enzyme inhibitors represent an alternative to diuretic-based combination therapy. The aim of the present study was to compare the antihypertensive efficacy of the combination enalapril 10 mg/ nitrendipine 20 mg (E/N) vs losartan 50 mg/hydrochlorothiazide 12.5 mg (L/H), assessed by 24-h ambulatory blood pressure monitoring. This multicentre, doubleblind, parallel study included 97 hypertensive patients (office diastolic blood pressure (DBP) 90-109 mmHg and daytime DBP 485 mmHg). After a 2-to 3-week period of single-blind placebo, they were randomized to receive double-blind treatment with E/N (n ¼ 48) or L/H (n ¼ 49) for a 4-week period. The primary outcome measure was the difference in 24-h DBP reduction between treatments from randomization to the end of the double-blind period. Secondary efficacy variables included differences in 24-h systolic (S) BP reduction, daytime, nighttime and office SBP and DBP reduction, proportion of responders and controlled patients, trough-to-peak ratio and smoothness indexes. Safety was assessed by the proportion of patients with adverse events and the detection of laboratory abnormalities. No significant differences were observed in the primary outcome measure. The group receiving E/N tended to show greater reductions in most measures (24 h, daytime and office SBP and DBP) and higher BP control rates, but only the difference in the rate of office SBP control (o140 mmHg) reached statistical significance (42.2 vs 22.4%; P ¼ 0.048). The trough-to-peak ratios and smoothness indexes were similar in both groups. The incidence of adverse events related to the treatment was 27.1% (95% CI 14.5-39.6%) in E/N-treated patients and
Introduction
Renin angiotensin system (RAS) inhibitors (either angiotensin converting enzyme inhibitors or angiotensin receptor blockers) combined with diuretics are the most widely used form of antihypertensive combination therapy, and it has been recently recommended for first-line therapy in patients with stage 2 hypertension. 1 However, the possible development of metabolic abnormalities induced by diuretic treatment, especially with the use of higher doses, has favored the development of other types of combination therapy that do not include diuretics.
The rationale for the combination of calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEI) has been widely described. [2] [3] [4] CCB are effective agents, achieving blood pressure (BP) control in a considerable proportion of patients. Moreover, in randomized controlled trials, CCB have demonstrated an important reduction of cardiovascular morbidity in hypertensive patients with systo-diastolic hypertension [5] [6] [7] [8] or with isolated systolic hypertension. 9 The amount of such reduction is comparable to other antihypertensive agents [6] [7] [8] 10, 11 or potentially even better in terms of protection against stroke. 10, 11 The main problem with the use of CCB lies with their tolerability, and especially with their ability to produce peripheral vasodilation. The use of long-acting CCB has reduced the incidence of treatment-related flushing and headache, but ankle oedema remains an important problem that limits tolerability in a considerable number of patients. Several controlled trials have revealed that the addition of ACEI to CCB reduces the incidence of ankle oedema, potentially improving tolerability while maintaining high efficacy. [12] [13] [14] The validity of this combination has been recently acknowledged by the European Society of Hypertension/European Society of Cardiology guidelines. 15 The fixed-dose combination of enalapril 10 mg/ nitrendipine 20 mg has been selected and developed by Grupo Vita for second-line treatment of hypertension according to current regulatory recommendations. 16, 17 The dose combination was selected in a factorial study, 18 and then confirmed in two comparative controlled trials against monotherapy with either enalapril or nitrendipine. 19 Another important factor in the use of new antihypertensive agents is their ability to maintain the antihypertensive effect during the complete dose interval. In order to better evaluate this effect, the use of ambulatory blood pressure monitoring (ABPM) has become an efficacious instrument. 20 ABPM allows simple calculations of both the trough-to-peak (T/P) ratio 21 and the smoothness index (SI), 22 as measures of the duration of action and the homogeneity of the antihypertensive effect, respectively.
The present study compares two fixed combinationsFenalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mgFin a group of essential hypertensive patients. Special attention is focused on the comparison of 24-h, diurnal and nocturnal BP reductions, as well as T/P ratios and SI.
Materials and methods

Design
This study was a multicentre, double-blind, randomized comparison of two parallel groups. After a 2-to 3-week single-blind placebo period, eligible patients were randomized to receive, in a single morning dose, the combination of enalapril 10 mg/ nitrendipine 20 mg or losartan 50 mg/hydrochlorothiazide 12.5 mg in a double-blind fashion during 4 weeks. Patients were evaluated at baseline, after 1 week of placebo treatment (only previously treated patients), at randomization and at the end of the study. ABPM was performed the day before randomization and on the last day of double-blind treatment.
Study population
Patients were included in the placebo period if they were between 18 and 75 years, had been diagnosed with essential hypertension at least 3 months before inclusion, had diastolic blood pressure (DBP) between 90 and 109 mmHg (between 95 and 109 mmHg if they were not under treatment), and gave their written informed consent. Patients were not included if they were women of childbearing potential, had stage III hypertension according to JNC-VI, 23 secondary or malignant hypertension, advanced retinopathy, heart failure class III or IV according to the New York Heart Association classification, arrhythmia, coronary disease or stroke within the last 6 months, chronic kidney or liver failure, uncontrolled diabetes mellitus, chronic nonsteroidal anti-inflammatory drug or nitrate treatment, prior drug or alcohol abuse, intolerance to study medication or related drugs or had received prior investigational treatment within 3 months. Patients were randomized to receive double-blind treatment if they had a daytime (from 1000 to 2000) DBP 485 mmHg, serum creatinine p150 mmol/l, liver enzymes p3 Â normal, bilirubin p1.5 Â normal and normal serum potassium levels.
Treatments
Patients received daily either placebo (lactose) (runin period, 2-3 weeks), a single tablet of the fixeddose combination of enalapril 10 mg+nitrendipine 20 mg (Eneas s , Grupo Vita) or a single tablet of losartan 50 mg+hydrochlorothiazide 12.5 mg. (Cozaar Plus s , Merck, Sharp & Dohme, Spain). Study medications were encapsulated to allow blinding. Dissolution tests ensured that the capsules did not interfere with the bioavailability of the active compounds. Clinical trial supplies were conditioned by Grupo Vita according to current Good Manufacturing Practice regulations and labelled according to a computer-generated randomization list in blocks of four. Eligible patients were randomized by consecutive assignment to sequential numbers related to double-blind medication. Patients were instructed to take double-blind treatment between 0700 and 0900, with the exception of the day of the visit.
Sample size
The study required 86 valid patients (43 per group) to detect a clinically relevant difference of 5 mmHg, assuming a standard deviation for 24-h DBP of 7 mmHg, a bilateral t-test with alpha error o5% and a statistical power of 90%. Sample wasting due to protocol deviations was estimated at 10%, thus requiring the randomization of 96 patients. 'Whitecoat' hypertension (daytime DBP p85 mmHg) was estimated to be present in 20-30%, and thus between 120 and 130 patients were planned to be included in the placebo phase.
Clinic blood pressure measurements
A mercury-in-glass sphygmomanometer was used to measure BP at trough (22-24 h of the last dose taken) twice, at 2-min intervals, after 5 min rest in a sitting position, the arm supported on a cushion and the cuff at heart level. A standard adult cuff was used for most subjects and a large cuff when required. DBP was recorded at disappearance of the Korotkoff sounds (Phase V). BP values were estimated as the mean of the two readings. If DBP differed by more than 5 mmHg between readings, a third measurement was performed and the mean of the two closest was taken as the valid BP. Measurements were performed by the same study assistant using the same manometer in each centre. Patients whose clinic blood pressure was o140/90 mmHg after 12 weeks of treatment were considered controlled. Patients exhibiting a reduction of DBP X10 mmHg and/or a reduction of systolic blood pressure (SBP) X20 mmHg at 12 weeks were defined as responders.
Noninvasive 24-h ambulatory blood pressure monitoring (24-h ABPM)
Ambulatory blood pressure was measured using an automated, noninvasive oscillometric device (SpaceLabs 90207, SpaceLabs Inc., Redmon, WA, USA). The appropriate cuff was placed on the nondominant arm and BP was registered automatically at 15-min intervals during the waking or daytime period (from 1000 to 2000), at 30-min intervals during the sleeping or night-time period (from 2400 to 0600) and at 20-min intervals during the remaining time (from 2000 to 2400 and from 0600 to 1000). Patients were instructed to take their placebo or double-blind medication immediately after the beginning of the record. The following parameters were obtained from each record in the 24-h, daytime and night-time periods: mean values and standard deviations of SBP, DBP and heart rate (HR). Patients whose daytime BP was o130/ 85 mmHg after 12 weeks of treatment were considered controlled. Patients exhibiting a reduction of 24-h DBP X5 mmHg and/or a reduction of 24-h SBP X10 mmHg at 12 weeks were defined as responders.
Calculation of the trough-to-peak ratio and the smoothness index Peak (P) and trough (T) effects of the drug were estimated using the methodology described by Omboni et al. 21 For both systolic and diastolic components, the residual effect at trough was calculated by ABPM, using the average BP over the 2-h period between 22 and 24 h after the dose on the treatment day subtracted from the average BP over the same period at baseline conditions. The peak effect was calculated in the same way by using the average BP over a 2-h period selected between 2 and 8 h after the dose on the treatment day subtracted from the average BP over the same period at baseline conditions. This period included the hour with the maximum fall in BP and the immediately adjacent hour in which the fall was more evident. The T/P ratio was calculated in ABPM responders.
The calculation of the SI takes into account all SBP and DBP changes induced by treatment over the 24 h, and was calculated for all patients who had completed pre-and post-treatment ABPM. Firstly, the average values of SBP and DBP for each hour of the 24-h monitoring period both before and after 4 weeks of treatment were calculated, thereby obtaining all hourly BP changes. The average of these hourly changes (DH) was divided by its standard deviation (SD DH ), which represents the dispersion of the antihypertensive effect over 24 h. The SI was calculated as the ratio DH/SD DH . 22 
Ethics
The Ethics Committee of each centre approved the study protocol before recruitment of the first patient. The clinical trial was conducted in compliance with the principles of Good Clinical Practice, the Declaration of Helsinki and Spanish regulations. Written informed consent from each patient was obtained before inclusion.
Statistical methods
Data management and statistical analysis were performed using SAS 6.12 for Windows. Safety analyses were conducted for all patients who took at least one study medication dose. Efficacy analyses were carried out for patients compliant with inclusion/exclusion criteria, having a valid final ABPM Enalapril/nitrendipine vs losartan/hydrochlorothiazide assessed by ABPMand with compliance of at least 80% of the study medication. Variables were described by their mean and standard deviation, median [ínterquartile range], or absolute and relative frequencies, as required. The main efficacy analysis compared the 24-h DBP reduction between treatments from randomization to study completion, using ANCOVA adjustments for sex and baseline 24-h DBP. Similar analyses were carried out for 24-h SBP, and for daytime, night-time and clinic BP. Other analyses (DBP and SBP control rates, proportion of responders and adverse events) were analysed by w 2 or Fisher's exact test.
Results
Patient disposition and baseline characteristics
The study included 126 patients recruited between April and November 2001 in nine Spanish centres. A total of 29 patients abandoned the study before randomization, mainly due to a low daytime DBP, assessed by ABPM. In all, 49 patients received losartan/hydrochlorothiazide (L/H) and 48 enalapril/nitrendipine (E/N). In this latter group, only 45 patients had an evaluable ABPM at the end of the study. The patient flow chart is shown in Figure 1 . Table 1 shows the baseline characteristics of patients randomized to each treatment group. As shown, no differences were observed in terms of age, gender, body mass index, duration of hypertension or proportion of active smokers. Moreover, office, 24-h, daytime and night-time SBP and DBP did not differ between treatment groups. Table 2 shows the comparison in BP reduction between the two groups of treatment. As shown, no significant differences were observed in the reduction of office, 24-h, daytime or night-time SBP and DBP. The group receiving E/N tended to show greater reductions in office, 24-h and daytime BP with respect to L/H, but only differences in daytime DBP reduction (2.8 [À0.3 to 5.8] mmHg; P ¼ 0.072) were at the limit of statistical significance (Figure 2) . Table 3 shows the proportion of responders and patients who achieved BP control in the two treatment groups. As shown, no differences were observed in response rates. The proportion of patients who achieved BP control was somewhat higher in E/N compared to L/H, but only differences in office SBP control rates were statistically significant (42.2% in E/N group vs 22.4% in L/H group; P ¼ 0.048).
Effect of treatments on blood pressure
Trough-to-peak ratios and smoothness indexes
Both L/H and E/N had T/P ratios higher than 0.5, and SI higher than 1, reflecting a residual Enalapril/nitrendipine vs losartan/hydrochlorothiazide assessed by ABPM A de la Sierra et al antihypertensive effect higher than 50% at the end of the dose interval and a homogeneous effect throughout 24 h. Table 4 shows values for systolic and diastolic T/P ratios and SI. No differences were observed between treatments.
Safety
The overall incidence of adverse events (AE) judged as being related to the treatment was 20.6%; 13 patients (27.1%) in the E/N group and seven patients (14.3%) in the L/H suffered from at least one related AE. No deaths or serious AE occurred during the study. Moreover, there were no changes in vital signs, including 24-h cardiac rate with any of the treatments used. Three patients in the E/N group and none in the L/H group abandoned the study due to mild AE. Table 5 shows the most-frequently- Enalapril/nitrendipine vs losartan/hydrochlorothiazide assessed by ABPM A de la Sierra et al reported adverse events in the two treatment groups. Table 6 shows the evolution of the main blood parameters in the two treatment groups. No significant abnormalities were detected in any parameter. The group treated with L/H showed an increase in serum triglycerides (from 134 7 73 to 152 7 105 mg/dl; P ¼ 0.077), which was considered neither clinically relevant nor significantly different (P ¼ 0.169) from that observed in the E/N group.
Discussion
This study shows that two different combination therapies for hypertension, E/N and L/H, reduced office and ambulatory BP in a group of essential hypertensive patients. The reduction in SBP obtained was about 20 mmHg for office BP and more than 16 mmHg for 24-h ambulatory BP. For DBP, the reduction obtained was greater than 10 mmHg for both office and 24-h ambulatory BP.
The combination of E/N seemed to be slightly more efficacious in reducing BP reduction than L/H. In fact, in the group treated with E/N, the reduction observed was between 2 and 3 mmHg greater for office BP, 1.5 mmHg greater for 24-h BP, and 3 mmHg greater for daytime BP. Unfortunately, the study was underpowered to detect the statistical significance of such differences, and only daytime SBP showed a difference between groups at the limit of statistical significance (P ¼ 0.072). Moreover, control rates were also somewhat higher in the E/N group, and the proportion of patients who achieved an office SBP o140 was significantly higher (42 vs 22%) with respect to L/H.
In recent years, there has been an increasing interest in the development of new combinations of antihypertensive therapies. This is based on the assumption that a BP goal of less than 140/90 mmHg must be achieved by most hypertensive patients, irrespective of age and gender, in order to confer better protection against cardiovascular disease. Moreover, lower BP targets are recommended for hypertensives with concomitant diabetes or renal disease. 1, 15, 24 Various clinical trials of cardiovascular protection with antihypertensive therapy have shown that between one-and two-thirds of patients require the use of combination therapy to normalize BP. 5, 9, 25, 26 The combination of an ACEI and a CCB represents an alternative to diuretic-based combinations. Theoretical advantages include a high antihypertensive potency and the lack of diuretic-induced metabolic abnormalities. [2] [3] [4] The present study was not designed to detect differences in possible metabolic changes between treatments, but patients treated with L/H showed an increase in serum triglycerides 26 Another important aspect of the present trial is the use of ABPM to compare antihypertensive drug combinations. ABPM is particularly useful in measuring the efficacy of antihypertensive therapy and it has been proposed that all newly marketed agents need to be evaluated by ABPM in pivotal clinical trials. 27 In addition, as ABPM is not significantly modified by the white coat effect, 20, 27 recruitment more adequately selects truly hypertensive individuals and allows the real BP lowering effect of treatments to be more accurately assessed. Moreover, ABPM is not substantially altered by placebo 28 and 24-h average BP values are much more reproducible than office values. 29 Thus, the reduction in BP obtained with both antihypertensive regimens in the present trial can be viewed as the true antihypertensive effect.
With respect to the effect on the circadian profile, we were not able to detect differences between treatments in either the T/P ratio or the SI. In both cases, the values obtained can be classified as good (T/P 40.5 and SI 41). However, the trial did show differences in the separate effects on daytime and night-time BP between treatments. E/N was superior to L/H in reducing daytime BP (at the limit of statistical significance), whereas the reduction in night-time BP was similar between groups. This may be important in terms of cardiovascular prognosis. Although all 24-h, daytime and night-time BP are powerful determinants of target organ damage, 30 daytime BP is generally considered as the main criterion for the diagnosis of hypertension based on ABPM. 31 In addition, an excessive BP reduction at night can lead to nocturnal ischaemia, especially in coronary patients. 32 In conclusion, E/N and L/H are equally effective and safe in reducing both office and ambulatory BP. The combination of E/N can represent an alternative to other forms of combination therapy in essential hypertensive patients who require more than one drug to achieve therapeutic goals.
